Cargando…
Viloxazine in the Treatment of Attention Deficit Hyperactivity Disorder
Attention deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in children. Over the past twenty years, research on the disease and its characteristics and treatment options has grown exponentially. The first-line pharmacologic treatment of ADHD is stimulants, which h...
Autores principales: | Edinoff, Amber N., Akuly, Haseeb A., Wagner, John H., Boudreaux, Megan A., Kaplan, Leah A., Yusuf, Shadman, Neuchat, Elisa E., Cornett, Elyse M., Boyer, Andrea G., Kaye, Adam M., Kaye, Alan D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718796/ https://www.ncbi.nlm.nih.gov/pubmed/34975586 http://dx.doi.org/10.3389/fpsyt.2021.789982 |
Ejemplares similares
-
The Role of Alpha-2 Agonists for Attention Deficit Hyperactivity Disorder in Children: A Review
por: Neuchat, Elisa E., et al.
Publicado: (2023) -
Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
por: Price, Maxwell Z., et al.
Publicado: (2023) -
Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
por: Edinoff, Amber N., et al.
Publicado: (2021) -
Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021) -
Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review
por: Edinoff, Amber N., et al.
Publicado: (2021)